Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.45 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.45 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6049741 | 0.91 | HTT (0.59) | HTTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL20703250 | 0.90 | SYK (0.54) | HTTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL28513293 | 0.89 | HTT (0.54) | HTTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL3693228 | 0.87 | HTT (0.61) | HTTSMN1; SMN2LMNAMEN1KMT2A | |
| Glycolic Acid SCHEMBL145941 | 0.86 | HTT (0.58) | HTTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL127919 | 0.86 | HTT (0.54) | HTTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL17501963 | 0.86 | MEN1 (0.49) | HTTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL16975020 | 0.86 | HTT (0.68) | HTTSMN1; SMN2LMNAL3MBTL1MAPT | |
| SCHEMBL10431132 | 0.85 | HTT (0.63) | HTTSMN1; SMN2LMNAL3MBTL1MAPT | |
| SCHEMBL5574078 | 0.85 | SYK (0.57) | HTTSMN1; SMN2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180332-B1 | DIFLUOROPYRROLIDINES AS OREXIN RECEPTOR MODULATORS | EOLAS THERAPEUTICS INC (US) | 2021-10-27 | — | — | EP | disclosed |
| US-10221170-B2 | Difluoropyrrolidines as orexin receptor modulators | EOLAS THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170226103-A1 | DIFLUOROPYRROLIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2017-08-10 | — | — | US | disclosed |
| EP-3180332-A1 | DIFLUOROPYRROLIDINES AS OREXIN RECEPTOR MODULATORS | Eolas Therapeutics Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016025669-A1 | DIFLUOROPYRROLIDINES AS OREXIN RECEPTOR MODULATORS | EOLAS THERAPEUTICS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016025669-A1 | DIFLUOROPYRROLIDINES AS OREXIN RECEPTOR MODULATORS | EOLAS THERAPEUTICS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221170-B2 | Difluoropyrrolidines as orexin receptor modulators | HCRTR2, OPRD1, HCRTR1 | HTT 2056/4885SMN1; SMN2 4808/4885LMNA 3826/4885 |
| US-20170226103-A1 | DIFLUOROPYRROLIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, OPRD1, HCRTR1 | HTT 2056/4885SMN1; SMN2 4808/4885LMNA 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.